Antifibrogenic effects of tamoxifen in a rat model of periportal hepatic fibrosis

Liver International

Volumn 29, Issue 2, 2009, Pages 308-314

  Ryu, Soo Hyung ^a   Chung, Young Hwa ^b   Lee, Jae Kyun ^b   Kim, Jeong A ^b   Shin, Jung Woo ^b   Jang, Myoung Kuk ^c   Park, Neung Hwa ^b   Lee, Han Chu ^b   Lee, Yung Sang ^b   Suh, Dong Jin ^b  

^a Inje University College of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

Hepatic fibrosis; Tamoxifen; TGF 1; Type I TGF receptor

Indexed keywords

MESSENGER RNA; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; HISTOPATHOLOGY; LIVER FIBROSIS; LIVER PROTECTION; MALE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION;

ANIMALS; COLLAGEN; DNA PRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; LIVER CIRRHOSIS; MALE; PROPANOLS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA, MESSENGER; STATISTICS, NONPARAMETRIC; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 58149494656     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01811.x     Document Type: Article

References (47)

1. Takamoto H, Matsuoka M, French SW. Experimental models of hepatic fibrosis: A review. Semin Liver Dis 1990; 10: 56-65.
2. Cameron GR, Karunaratne WAE. Carbon tetrachloride cirrhosis in relation to liver regeneration. J Pathol Bacteriol 1936; 42: 1-21.
3. Morrione TG. Factors influencing collagen content in experimental cirrhosis. Am J Pathol 1949; 25: 273-85.
4. Jung SA, Chung YH, Park NH, et al. Experimental model of hepatic fibrosis following repeated periportal necrosis induced by allylalcohol. Scand J Gastroenterol 2000; 35: 969-75.
5. Flisiak R, Prokopowicz D. Transforming growth factor-β1 as a surrogate marker of hepatic dysfunction in chronic liver disease. Clin Chem Lab Med 2000; 38: 1129-31.
6. Graham MF, Bryson GR, Diegelmann RF. Transforming growth factor-β1 selectively augments collagen synthesis by human intestinal smooth muscle cells. Gastroenterology 1990; 99: 447-53.
7. Dignass AU, Podolsky DK. Cytokine modulation of intestinal epithelial cell restitution: Central role of transforming growth factor-β1. Gastroenterology 1993; 105: 1323-32.
8. Marek A, Brodzicki J, Liberek A, Korzon M. TGF-β (transforming growth factor-β) in chronic inflammatory conditions - a new diagnostic and prognostic marker? Med Sci Monit 2002; 8: 145-51.
9. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-8.
10. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med 1994; 331: 1286-92.
11. Roth S, Michel K, Gressner AM. (Latent) Transforming growth factor β in liver parenchymal cells, its injury dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 1998; 27: 1003-12.
12. Shin JW, Chung YH, Park MI, et al. The effects of tamoxifen on human hepatocellular carcinoma cell proliferation and transforming growth factor-beta 1 expression. Korean J Hepatol 2003; 9: 10-6. [In Korean].
13. Batt KP, Ludwig J. Chronic hepatitis: An update on terminology and reporting. Am J Surg Path 1995; 19: 1409-17.
14. Castilla-Cortazar I, Garcia M, Muguerza B, et al. Hepatoprotective effects of insulin-like growth factor I in rats with carbon tetrachloride-induced cirrhosis. Gastroenterology 1997; 113: 1682-91.
15. Jimenez W, Pares A, Caballeria J, et al. Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method. Hepatology 1985; 5: 815-8.
16. Bissell DM, Maher JJ. Hepatic fibrosis and cirrhosis. In: Jakim D, Boyer TD, eds. Hepatology: A Textbook of Liver Disease, 3rd edn. Philadelphia: WB Saunders, 1996; 506-25.
17. Cortez-Pinto H, Alexandrino P, Camilo ME, et al. Lack of effect of colchicine in alcoholic cirrhosis: Final results of a double blind randomized trial. Eur J Gastroenterol Hepatol 2002; 14: 377-81.
18. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis or cirrhosis. Liver 2001; 21: 129-36.
19. Schaff Z, Lapis K, Szende B, et al. The effect of d - penicillamine on experimental liver cirrhosis induced by CCl 4. Morphol Igazsagugyi Orv Sz 1990; 30: 161-9. [In Hungarian].
20. Okuno M, Kojima S, Akita K, et al. Retinoids in liver fibrosis and cancer. Front Biosci 2002; 1: D204-18.
21. + exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology 1999; 116: 1155-66.
22. Wang YQ, Ikeda K, Ikebe T, et al. Inhibition of hepatic stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2000; 32: 980-9.
23. Fernandez I, Torres I, Moreira E, Fontana L, Gil A, Rios A. Influence of administration of long-chain polyunsaturated fatty acid on process of histological recovery in liver cirrhosis produced by oral intake of thioacetamide. Dig Dis Sci 1996; 41: 197-207.
24. Al Rabi N, Graziani R, Cerruto MA, Baldassarre R, Ficarra V, Artibani W. Clinical and radiological evolution of a case of idiopathic retroperitoneal fibrosis treated with Tamoxifen. Scand J Urol Nephrol 2002; 36: 391-2.
25. Al-Salman J, Makhdomi AR. Treatment of retroperitoneal fibrosis with tamoxifen. South Med J 2002; 95: 947.
26. Frankart L, Lorge F, Donckier J. Tamoxifen for retroperitoneal fibrosis. Postgrad Med J 1997; 73: 653-4.
27. Dabelic N, Jukic T, Labar Z, Novosel SA, Matesa N, Kusic Z. Riedel's thyroiditis treated with tamoxifen. Croat Med J 2003; 4: 239-41.
28. De M, Jaap A, Dempster J. Tamoxifen therapy in steroid resistant Reidel's thyroiditis. Scott Med J 2001; 46: 56-7.
29. Hu D, Hughes MA, Cherry GW. Topical tamoxifen - a potential therapeutic regime in treating excessive dermal scarring. Br J Plast Surg 1998; 51: 462-9.
30. Chau D, Mancoll JS, Lee S, et al. Tamoxifen downregulates TGF-beta production in keloid fibroblasts. Ann Plast Surg 1998; 40: 490-3.
31. Kuhn MA, Wang X, Payne WG, Ko F, Robson MC. Tamoxifen decreases fibroblast function and downregulates TGF (beta2) in dupuytren's affected palmar fascia. J Surg Res 2002; 103: 146-52.
32. Mikulec AA, Hanasono MM, Lum J, Kadleck JM, Kita M, Koch RJ. Effect of tamoxifen on transforming growth factor beta 1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001; 3: 111-4.
33. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver steatosis: The role of glucose intolerance. Eur J Gastroenterol Hepatol 2004; 16: 593-8.
34. Wogan GN. Review of the toxicology of tamoxifen. Semin Oncol 1997; 24: S87-97.
35. Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP. The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 2005; 45: 177-202.
36. Lewindon PJ, Pereira TN, Hoskins AC, et al. The role of hepatic stellate cells and transforming growth factor-beta (1) in cystic fibrosis liver disease. Am J Pathol 2002; 160: 1705-15.
37. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: D793-807.
38. Flisiak R, Pytel-Krolczuk B, Prokopowicz D. Circulating transforming growth factor beta (1) as an indicator of hepatic function impairment in liver cirrhosis. Cytokine 2000; 12: 677-81.
39. Lanvin O, Guglielmi P, Fuentes V, et al. TGF-beta1 modulates Fas (APO-1/ CD95)-mediated apoptosis of human pre-B cell lines. Eur J Immunol 2003; 33: 1372-81.
40. Kolek O, Gajkowska B, Godlewski MM, Motyl T. Antiproliferative and apoptotic effect of TGF-beta (1) in bovine mammary epithelial BME-UV1 cells. Comp Biochem Physiol C Toxicol Pharmacol 2003; 134: 417-30.
41. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784-800.
42. Sergeev PV, Chukaev SA, Korovkina YA. Effects of sex hormones and antihormones on the activity of redox system enzymes of human erythrocyte glutathione. Bull Exp Biol Med 1997; 8: 786-8.
43. Miccadei S, Nakae D, Kyle ME, Gilfor D, Farber JL. Oxidative cell injury in the killing of cultured hepatocytes by allyl alcohol. Arch Biochem Biophys 1988; 265: 302-10.
44. Piek E, Helden CH, Ten Dijke P. Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 1999; 13: 2105-24. (seminar 70).
45. Massimo P, Fabio M. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001; 21: 397-416.
46. Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29: 1730-8.
47. Pannul J, Gore-Hyer E, Yamanaka M, et al. An increased transforming growth factor beta receptor type I: type II ratio contributes to elevated collagen protein synthesis that is resistant to inhibition via a kinase-deficient transforming growth factor beta receptor type II in scleroderma. Arthritis Rheum 2004; 50: 1566-77.